<DOC>
	<DOC>NCT02433730</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of testosterone replacement therapy in men with low testosterone due to opioid treatment on body composition, the haemostatic system, glucose metabolism, muscle function, pain sensitivity, pain modulation, lipids, sexual function and quality of life. Male patients on opioids for non-malignant diseases aged 18-59 years diagnosed with hypogonadotrophic hypogonadism, referred from day hospitals and outpatient populations. 40 patients are randomized to either testosterone undecanoate i.m. or placebo i.m., i.e. 20 patients per arm A double blinded randomized placebo controlled trial</brief_summary>
	<brief_title>Testosterone Therapy in Hypogonadal Men Treated With Opioids</brief_title>
	<detailed_description>The study duration is 24 weeks. Patients are treated with Testosterone Undecanoate 1000 mg/4 ml, intramuscular (i.m.) or placebo at 0, 6 and 18 weeks. Outcome measures will be evaluated at 0 and 14 weeks.</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male patients 1859 years Treatment with opioid for &gt;3 months, daily dose &gt;50100 mg Total testosterone &lt; 10 mmol/L Follicle Stimulating Hormone (FSH)/Luteinizing Hormone (LH) levels normal og below normal laboratory values Normal prolactin levels Hematocrit&gt; 54% at screening Prostate Specific Antigen (PSA) &gt; 3 ng/ml Routine blood sample values above range (thyroid stimulating hormone; ionized calcium, hemoglobin, liver and kidney function tests) Severe organic and mental disease Past or present prostate cancer og breastcancer Past or present liver tumors og acute or chronic liver diseases Any current diagnosis og cancer Acute thromboembolic disease Previous venous thrombotic embolism and cerebrovascular disease Uncontrolled hypertension Chronic debilitating disease Epilepsy or migraine not adequately controlled by therapy Severe benign prostate hypertrophy with symptom score &gt;19 Sleep apnea Alcohol or drug abuse Implantation of sustained action sex hormone in the last 12 months Use of oral, buccal or transdermal testosterone in the last two weeks Blood coagulation irregularities presenting af risk of bleeding after intramuscular injection Treatment with glucocorticoids &gt; 5 mg/day or 5 alfa reductase inhibitors Hypersensitivity to Nebido Body mass index &gt; 40 kg/m2</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>